Atencion primaria · 2025
[Effectiveness of GLP-1 receptor agonists in managing patients with type 2 diabetes].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bejarano Romero Ferran, Aragó Molés Vicente, Morón Porrúa Daniel, López Guerrero Eva, Suñer Barriga Helena, Canadell Vilarrasa Laura
Аннотация
OBJECTIVE: To evaluate the effectiveness of GLP-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus and to describe their clinical characteristics.
DESIGN: Retrospective cohort study based on electronic health records. SITE: Health centres of the Primary and Community Care Management (GAPiC) Camp de Tarragona.
PARTICIPANTS: Patients aged ≥18 years with a diagnosis of type 2 diabetes mellitus on treatment with an GLP-1 RA.
MAIN MEASUREMENTS: Demographic variables, glycosylated haemoglobin (HbA1c) and weight/BMI were collected to assess effectiveness; and clinical variables were recorded to assess safety.
RESULTS: A total of 1227 patients (50.2% male) were included. A mean average HbA1c% reduction of 0.50% in HbA1c (p<0.001), weight reduction of 3.08kg weight (p<0.001) and BMI reduction of 0.99kg/m2 (p<0,001) were observed after 472 days of average treatment.
CONCLUSIONS: GLP-1 RAs are effective in glycemic control and weight reduction in clinical practice. The results are consistent with international studies, although somewhat lower than pivotal trials.
DESIGN: Retrospective cohort study based on electronic health records. SITE: Health centres of the Primary and Community Care Management (GAPiC) Camp de Tarragona.
PARTICIPANTS: Patients aged ≥18 years with a diagnosis of type 2 diabetes mellitus on treatment with an GLP-1 RA.
MAIN MEASUREMENTS: Demographic variables, glycosylated haemoglobin (HbA1c) and weight/BMI were collected to assess effectiveness; and clinical variables were recorded to assess safety.
RESULTS: A total of 1227 patients (50.2% male) were included. A mean average HbA1c% reduction of 0.50% in HbA1c (p<0.001), weight reduction of 3.08kg weight (p<0.001) and BMI reduction of 0.99kg/m2 (p<0,001) were observed after 472 days of average treatment.
CONCLUSIONS: GLP-1 RAs are effective in glycemic control and weight reduction in clinical practice. The results are consistent with international studies, although somewhat lower than pivotal trials.